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Background: Keratins 8/18 (K8/K18) are established hepatoprotective proteins and K8/K18 variants predispose to
development and adverse outcome of multiple liver disorders. The importance of K8/K18 in alcoholic liver disease
as well as in established cirrhosis remains unknown.
Methods: We analyzed the K8 mutational hot-spots in 261 prospectively followed-up patients with alcoholic
cirrhosis (mean follow-up 65 months). PCR-amplified samples were pre-screened by denaturing high-performance
liquid chromatography and conspicuous samples were sequenced.
Results: 67 patients developed hepatocellular carcinoma (HCC) and 133 died. Fourteen patients harbored
amino-acid-altering K8 variants (5xG62C, 8xR341H). The presence of K8 variants did not associate with development
of HCC (log-rank=0.5) or death (log-rank=0.7) and no significant associations were obtained for the single K8
variants after a correction for multiple testing was performed.
Conclusions: Keratin variants are expressed in a low percentage of patients with alcoholic cirrhosis and do not
influence HCC development. Further studies conducted in larger prospective cohorts are needed to find out
whether presence of K8 R341H variant predispose to non-HCC-related liver mortality.
Keywords: Hepatocellular carcinoma, R341H, MortalityBackground
Alcohol consumption induces a variety of hepatic
changes ranging from asymptomatic fatty liver to end-
stage liver failure and represents the leading cause of
liver-related mortality in western countries [1]. Although
the pathogenesis of alcoholic liver disease (ALD) is in-
completely understood, genetic factors play a significant
role [2]. While most studies focused on genes involved
in oxidative stress response, hepatic lipid storage, alcohol
consumption/metabolism as well as liver inflammation
and fibrosis [2], cytoskeletal proteins are also established* Correspondence: pstrnad@ukaachen.de
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reproduction in any medium, provided the orALD targets [3]. Among them, keratins represent at-
tractive candidates to serve as modifier genes in ALD,
given that (i) keratins are established liver disease modi-
fiers [4-6]; (ii) ALD leads to a characteristic redistribu-
tion of K8/K18 network with formation of Mallory-Denk
bodies and keratin redistribution was previously shown
to be affected by presence of keratin variants [7,8];
(iii) oxidative stress is an integral part of ALD and pres-
ence of keratin variants primes transgenic animals
towards oxidative stress [9].
Keratins (Ks) constitute the largest subgroup of inter-
mediate filaments and are expressed predominantly in
epithelial tissues as well as epithelial appendages [10,11].
They can be further subdivided into type I (K9-K28) and
type II proteins (K1-K8 and K71-K80), which are both
needed to form obligate heteropolymers [10,12].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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type I-type II keratin pair [12]. Adult hepatocytes are
unique in that they produce only K8/K18 while other
cells typically exhibit a more complex keratin expression
pattern [12]. The simple keratin composition is likely re-
sponsible for the fact that liver is particularly sensitive to
the perturbations in keratin system. To that end, mul-
tiple transgenic mice lacking K8/K18 or expressing
mutated proteins are susceptible to a variety of different
liver stresses [4]. Human association studies further sup-
port these data by demonstrating that K8/K18 variants
predispose to development and severe outcome of vari-
ous liver disorders [4-6]. K8/K18 variants are detected in
4-5% of Caucasian controls with K8 G62C/R341H being
the most common ones reaching a frequency of 1.5 and
3.2%, respectively [6,13]. K8/K18 variants are not only
overrepresented in subjects with multiple liver disorders,
but also predispose to liver fibrosis development in
patients with chronic hepatitis C and primary biliary cir-
rhosis as well as to adverse outcome of acute liver failure
[4-6]. While these data are intriguing, it remains unclear,
to what extent K8/K18 variants influence the prognosis
of subjects with ALD, particularly those with already
established liver cirrhosis.
Although K8/K18 are widely established hepatoprotec-
tive proteins [4], their role is likely restricted to specific
liver stresses. For example, K18 R90C variant increases
the susceptibility of transgenic animals to Fas-, but not
TNFa-mediated liver injury as well as to thioacetamide-,
but not carbon tetrachloride-induced liver fibrosis devel-
opment [4,14]. Moreover, exonic K8/K18 variants do not
significantly modulate liver fibrosis development in
patients with hereditary hemochromatosis [15]. To fur-
ther delineate the importance of K8/K18 variants in spe-
cific human liver disorders, we studied the impact of
these variants on overall and liver-related mortality as
well as on development of hepatocellular carcinoma
(HCC) in a prospectively monitored cohort of French
patients with alcohol-related liver cirrhosis.
Methods
Selection of patients
The present work was part of a prospective study con-
ducted in cirrhotic patients that was aimed at assessing
the performance of HCC screening procedures as well
as the rates and risks factors of liver cancer development
in the course of various liver diseases [16]. The protocol
obtained approval from the Ethics Committee (CPP,
Aulnay-sous-Bois, France). All patients gave written
informed consent to participate in the study and all re-
search carried out in participants was in compliance
with the 1975 Declaration of Helsinki as reflected in a
priori approval by the institution's human research
committee.In the present study, we included all new patients re-
ferred to the liver unit of Hôpital Jean Verdier (Bondy,
France) between 1 January 1995 and 31 December 2005,
who fulfilled the following criteria: 1) biopsy-proven liver
cirrhosis; 2) daily alcohol intake >80 g per day 3) no in-
fection from the human immunodeficiency virus or
hepatitis B or C viruses; 4) no evidence of HCC at the
time of inclusion as judged by negative ultrasonographic
findings and a serum a-fetoprotein (AFP) level of
<50 ng/mL; 5) Caucasian origin and residence in France;
6) acceptance of a regular follow-up and periodical HCC
screening. A total of 261 patients were recruited.
The study started with the detection of liver cirrhosis
on the first liver biopsy and all patients were prospect-
ively evaluated at least twice a year by a physical examin-
ation, liver ultrasound and measurement of serum AFP
levels. When a HCC was suspected, computer tomog-
raphy, and/or magnetic-resonance imaging and/or a
guided liver biopsy was performed according to the
Barcelona criteria [17]. HCC was diagnosed when at
least one of the following criteria were fulfilled:
1. Histological evidence
2. Congruent demonstration of a focal lesion >2 cm in
size, and arterial hypervascularization, as assessed by
two different imaging techniques
3. A combination of one imaging technique plus a
serum AFP level of ≥400 ng/mL.
Gender, age, BMI, past history of diabetes mellitus,
presence of ascites or hepatic encephalopathy, se-
rum bilirubin, albumin and prothrombin levels, serum
alanine-aminotransferase activity, and serum aspartate-
aminotransferase activity were recorded at the time of
inclusion. Daily alcohol intake was obtained by per-
sonal interview. The two main end-points were the oc-
currence of HCC and the occurrence of death or liver
transplantation (the date of liver transplantation was
considered as the day of death). Otherwise, the follow-
up ended at the last recorded visit (or information
taken) prior to 31 August 2011. This deadline was
used to upgrade the patients’ file using our computer-
ized database, as well as to obtain information by
contacting the patients, their relatives or general
practitioner.
Genetic analysis
Genomic DNA was isolated from peripheral blood
mononuclear cells using a commercially available kit
according to manufacturer’s instructions (Amersham,
GE Healthcare). Exons 1 and 6 of keratin 8 were poly-
merase chain reaction-amplified using established pri-
mers [18] and a “hot-start” Amplitaq Gold DNA
Polymerase (Applied biosystems; Foster City, CA). The
Table 1 Characteristics of the cohort of patients with
alcoholic liver cirrhosis
Patients with alcoholic cirrhosis
(n=261)
Age (years)a 56.8±0.6
Male gender b 202 (77.4)
Child-Pugh score a 7.7±0.1
Prothrombin activity (%)a 62.5±1.2
Bilirubin (μmol/L) a 47.6±3.6
Albumin (g/L) a 35.8±0.3
Platelet count (103/mm3) a 137.2±3.2
AST (ULN) a 2.2±0.08
ALT (ULN) a 1.5±0.1
GGT (ULN) a 6.4±0.4
Follow-up (months) a 65.8±2.4
HCC b 67 (25.6)




ALT, alanine aminotransferase, AST, aspartate aminotransferase, GGT, gamma-
glutamyl transferase, HCC, hepatocellular carcinoma, ULN, upper limit of
normal.
aMean ± SEM (standard error of the mean).
bNumber (percentage) of patients.
Usachov et al. BMC Gastroenterology 2012, 12:147 Page 3 of 6
http://www.biomedcentral.com/1471-230X/12/147specificity of the amplification was confirmed by sequen-
cing. PCR products were analyzed for presence of het-
erozygous variants by denaturing high-performance
liquid chromatography (DHPLC) using a WAVE DNA
Fragment Analysis system. Samples with “shifted” elu-
tion pattern were purified with a Qiaquick PCR purifica-
tion kit (Qiagen) and sequenced.
Statistical methods
Qualitative variables were compared using Fisher’s exact
test, the chi-squared test or the chi-squared trend test
with 1° of freedom, whereas quantitative variables were
compared using the non-parametric Kruskal–Wallis test.
The Kaplan–Meier method was used to estimate the oc-
currence of HCC/death for each parameter noted at en-
rolment. The distribution of death and HCC were
compared with the log-rank test. A significant level
<0.10 was used to select the variables for the Cox’s pro-
portional hazards model, using a stepwise backward pro-
cedure with a threshold of a=0.05. Variables associated
with risk of death or HCC, based on knowledge and
findings from previous studies were also selected for
multivariate analyses (age, gender, BMI, diabetes, Child-
Pugh score, platelet count). Statistical analyses were per-
formed using the SAS System Package version 8.02 (SAS
Institute, Cary, NC). All reported P values are two-tailed.




A total of 261 patients were enrolled in this study. Their
initial characteristics are summarized in Table 1. The
mean follow-up period was 65 months with extremes
ranging from 22 to 150 months. During the study
period, 24/261 patients (9.2%) were lost to follow-up
after at least 2 years of HCC screening. During follow-
up, 67 developed HCC and 133 died or underwent liver
transplantation (n=17). In all but 5 cases, death was at-
tributable to liver disease caused by advanced HCC, vari-
ceal bleeding and/or complications caused by hepatic
failure. The non-HCC-related complications were the
main causes of death.
Lack of influence of keratin variants on outcomes
Our genetic analysis detected K8 G62C and K8 R341H
variants in 5 and 8 patients respectively. K8 I63V variant
was seen in one person and no intronic variants were
observed (Table 2). When stratifying the population
according to the presence of variants in K8 exon 1 (K8
G62C/I63V), exon 6 (K8 R341H) or all keratin variants
(n=14), the baseline severity of liver disease as well as
demographic and clinical data were similar among the
variant carriers and non-carriers (data not shown).Similar rates of complications during follow-up were
observed between patients bearing the K8E1 variants
and the remains subjects [HCC occurrence 2/6 (33.3%)
vs. 65/255 (25.5%), P=0.6; death: 2/6 (33.3%) vs. 126/255
(49.4%), P=0.4). This observation was confirmed by the
Kaplan-Meier method as the K8E1 mutation carriage
was not associated with the development of HCC
(HR=0.8 [0.1–3.3], log-rank=0.7) or death (HR=0.4 [0.1–
1.6], log-rank=0.2) when considering the occurrence of
these events over time. Similarly, the presence of the K8
R341H variant was not associated with HCC occurrence
[2/8 (25.0%) vs. 65/253 (25.7%), P=0.9], a finding that
was confirmed by the Kaplan-Meier method (HR= 0.7
[0.1-3.1], log-rank =0.7, Figure 1A). On the other hand,
patients carrying K8 R341H variant had an apparent
higher rate of overall mortality [7/8 (87.5%) vs. 121/253
(47.8%), P=0.02] that was due to higher incidence of
non-HCC liver-related death [5/8 (62.5%) vs. 68/253
(26.9%), P=0.02]. However, this negative impact was not
observed when taking into account the occurrence of
death over time, whether for overall mortality (HR=1.5
[0.7-3.3], log-rank =0.2) or death non-attributable to
HCC (HR=2.0 [0.8-5.0], log-rank =0.1, Figure 1B).
In addition, we analyzed the impact of presence of any
K8 variant on the disease outcome. We did not observe
any influence on the mortality (HR= 0.7 [0.6-2.7], log-
rank =0.5) or HCC occurrence (log-rank=0.7, Figure 2),






K8 E1 184 G→T G62C 5 1,9
187 A→G I63V 1* 0,38
E6 1022 G→A R341H 8 3,1
Total 14 (13)* 5,4 (5,0)
*Based on previous studies, K8 I63V represents a polymorphism rather than a
biologically relevant K8 variant.
Figure 1 The significance of K8 R341H variant in patients with
alcoholic liver cirrhosis. The impact of K8 R341H variant on
development of hepatocellular carcinoma (HCC) (A) and on
non-HCC-related liver mortality (B) was studied in subjects with
alcoholic liver cirrhosis using the Kaplan–Meier method. While
K8 R341H variant was not associated with HCC development
(log-rank =0.7), patients carrying K8 R341H variant displayed a trend
towards increased end-stage liver disease mortality (HR=2.0 [0.8-5.0],
log-rank=0.1).
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analyses (0.7 and 0.5 respectively). Finally, using the
Cox’s proportional hazards model, the presence of kera-
tin variants was not associated with HCC occurrence in
multivariate analysis. The multivariate model selected
three independent features associated with the develop-
ment of HCC in this cohort, namely older age, male
gender, and high Child-Pugh score.
Discussion
In the presented study, we analyzed the importance of K8
variants in a cohort of French patients with alcoholic liver
cirrhosis. K8 R341H variant was the most common variant
and was found in 8 subjects (variant frequency 3.1%), which
lies well below the frequencies seen in US Caucasians with
end-stage liver disease or acute liver failure (5.1 and 7.2%,
respectively, Table 3) [6,19]. On the other hand, similar
variant frequencies were observed in US control subjects as
well as in a German cohort of patients with chronic hepa-
titis C (Table 3) [18,19]. Similarly, the frequency of K8
G62C variant found in our cohort is comparable to their
occurrence in a large cohort of German control subjects
(1.9 vs 1.6-1.8%, Table 3) [20,21]. Although the frequency of
keratin variants in French population remains unknown,
these data strongly suggest that K8 variants are not overre-
presented in our cohort of patients with alcoholic liver
cirrhosis.Figure 2 Presence of K8 variants does not predispose to
development of hepatocellular carcinoma in subjects with
alcoholic liver cirrhosis. Kaplan–Meier method was used to
evaluate the development of hepatocellular carcinoma in subjects
who do/do not (K8+/K8-) carry K8 variants (HR=0.8 [0.3-2.1],
log-rank=0.7).













France ALC 261 5 (1,9) 8 (3,1) This study
Europe Controls 4167 65 (1,6) - [13]
Germany CHC 278 5 (1,8) 8 (2,9) [18]
US End-stage liver
disease
274 4 (1,5) 14 (5,1) [19]
Controls 268 1 (0,373) 8 (3,0)
Germany ALD 215 4 (1,9) - [21]
Controls 679 12 (1,8)
Germany Controls 560 9 (1,6) - [20]
Italy PBC 201 4 (2,0) 8 (4,0) [5]
Controls 200 0 3 (1,5)
US ALF 252 4 (1,6) 18 (7,2) [6]
ALC- Alcoholic Liver Cirrhosis, CHC-Chronic Hepatitis C, ALD- Alcoholic Liver
Disease, PBC- Primary Biliary Cirrhosis, ALF-Acute Liver Failure.
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outcome. Although keratins represent established tumor
markers [12,22], the analyzed K8 variants did not affect
the development of HCC. On the other hand, the pres-
ence of K8 R341H, but not K8 G62C or total K8 variants
predisposed to non-HCC-related liver mortality. Several
human association studies support the biological import-
ance of this variant. For example, K8 R341H was signifi-
cantly overrepresented in US patients with end-stage
liver disease versus the control subjects [19] and in
patients with acute liver failure, the presence of K8
R341H predisposed to adverse disease outcome [6].
While the higher rate of death in patients carrying K8
R341H variant is intriguing, a more powerful Kaplan-
Meier analysis, which takes into account not only the
number of events occurring during follow-up but also
their rapidity of onset and their respective weight in the
population, did not confirm these findings. Although this
finding should be interpreted cautiously due to the low
number of keratin variants in this cohort, the present
data suggest that K8 R341H variant may not affect the
outcome of alcoholic liver disease. This is supported by
the fact that although keratins are well established hepa-
toprotective proteins, they do not offer protection in all
stress situations. For example, amino-acid-altering kera-
tin variants do not enhance TNFa-related liver toxicity
[4] and do not predispose to progression of liver disease
in patients with hemochromatosis [15,23].
Conclusions
Our study analyzed the impact of keratin variants on
disease outcome in patients with alcohol-related liver
cirrhosis. Although K8 R341H variant may predispose to
development of end-stage liver failure, the limitednumbers of patients available as well as the low fre-
quency of keratin variants within the cohort make it im-
possible for this study to conclusively clarify the
significance of keratin variants in subjects with alcohol-
related liver cirrhosis. Furthermore, these findings must
be validated in other populations, even though the co-
hort used herein is well studied and was used in the past
to replicate several established genetic associations
[24,25]. Up to date, all reports (including ours) focusing
on genetic predisposition to life-threatening events in
cirrhotic patients are prone to interpretation bias related
to low power analyses, a limitation that will not be over-
come until coordinated work of international research
consortia allows the establishment of large cohorts of
patients.
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